Nykode Therapeutics ASA
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 173
- Market Cap
- $207.4M
- Website
- http://www.nykode.com
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
- Conditions
- HPV-Related MalignancyCervical CancerHPV-Related Cervical Carcinoma
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 130
- Registration Number
- NCT06099418
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
- Conditions
- HPV Positive Oropharyngeal Squamous Cell CarcinomaHNSCC
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 51
- Registration Number
- NCT06016920
- Locations
- 🇫🇷
CRLC Val d'Aurelle - Institut de Recherche en Cancerologie de Montpellier (IRCM), Montpellier, France
🇨🇿Fakultni nemocnice Olomouc, Olomuoc, Olomouc, Czechia
🇫🇷Hospices Civils De Lyon, Lyon, France
A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
- Conditions
- COVID-19Infection ViralInfections
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 68
- Registration Number
- NCT05069623
- Locations
- 🇳🇴
Haukeland University Hospital, Klinisk Forskningspost, Bergen, Norway
🇳🇴Oslo University Hospital Ullevål Sykehus, Dept. Infection Diseases, Oslo, Norway
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
- Conditions
- Solid Tumors, Adult
- Interventions
- Biological: VB10.NEO
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 26
- Registration Number
- NCT05018273
- Locations
- 🇺🇸
The Regents of the University of California, San Francisco, California, United States
🇺🇸Yale Cancer Institute, New Haven, Connecticut, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
- Conditions
- Cervical CancerCervix Cancer
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 52
- Registration Number
- NCT04405349
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇪Hopital de Libramont, Bruxelles, Belgium
🇧🇪Universitair Ziekenhuis Gent (Uz Gent), Gent, Belgium
- Prev
- 1
- 2
- Next
News
Epitopea Strengthens Leadership Team as RNA-Based Cancer Immunotherapy Platform Advances Toward Clinical Trials
Epitopea has appointed key executives including Siri Brinchmann-Hansen Torhaug as Head of Oncology Development and Gertrud Koefoed Rasmussen as Head of Development Operations to accelerate clinical development of its CryptiVax™ RNA-based immunotherapies.
Nykode Therapeutics Presents Promising Immunotherapy Data for HPV16-Positive Cancer and Solid Tumors at ASCO 2025
Nykode Therapeutics has presented new clinical data at ASCO 2025 for two cancer immunotherapy candidates, VB10.16 and VB10.NEO, both showing robust immune responses when combined with atezolizumab.
BioNTech, Moderna Lead the Race in Personalized Cancer Vaccine Development with Promising Clinical Results
Personalized cancer vaccines are emerging as a transformative approach in oncology, with BioNTech, Moderna, and myNEO Therapeutics leading development using mRNA technology refined during the COVID-19 pandemic.